Robustness of radiomics features on 0.35 T magnetic resonance imaging for magnetic resonance-guided radiotherapy.

MR-guided radiotherapy Radiomics Robustness

Journal

Physics and imaging in radiation oncology
ISSN: 2405-6316
Titre abrégé: Phys Imaging Radiat Oncol
Pays: Netherlands
ID NLM: 101704276

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 27 02 2024
revised: 15 07 2024
accepted: 16 07 2024
medline: 14 8 2024
pubmed: 14 8 2024
entrez: 14 8 2024
Statut: epublish

Résumé

MR-guided radiotherapy adds the precision of magnetic resonance imaging (MRI) to the therapeutic benefits of a linear accelerator. Prior to each therapeutic session, an MRI generates a significant volume of imaging data ripe for analysis. Radiomics stands at the forefront of medical imaging and oncology research, dedicated to mining quantitative imaging attributes to forge predictive models. However, the robustness of these models is often challenged. To assess the robustness of feature extraction, we conducted reproducibility studies using a 0.35 T MR-linac system, employing both a specialized phantom and patient-derived images, focusing on cases of pancreatic cancer. We extracted shape-based, first-order and textural features from patient-derived images and only first-order and textural features from phantom-derived images. The impact of the delay between simulation and first fraction images was also assessed with an equivalence test. From 107 features evaluated, 58 (54 %) were considered as non-reproducible: 18 were uniformly inconsistent across both phantom and patient images, 9 were specific to phantom-based analysis, and 31 to patient-derived data. Our findings show that a significant proportion of radiomic features extracted from this dual dataset were unreliable. It is essential to discard these non-reproducible elements to refine and enhance radiomic model development, particularly for MR-guided radiotherapy in pancreatic cancer.

Sections du résumé

Background and purpose UNASSIGNED
MR-guided radiotherapy adds the precision of magnetic resonance imaging (MRI) to the therapeutic benefits of a linear accelerator. Prior to each therapeutic session, an MRI generates a significant volume of imaging data ripe for analysis. Radiomics stands at the forefront of medical imaging and oncology research, dedicated to mining quantitative imaging attributes to forge predictive models. However, the robustness of these models is often challenged.
Materials and methods UNASSIGNED
To assess the robustness of feature extraction, we conducted reproducibility studies using a 0.35 T MR-linac system, employing both a specialized phantom and patient-derived images, focusing on cases of pancreatic cancer. We extracted shape-based, first-order and textural features from patient-derived images and only first-order and textural features from phantom-derived images. The impact of the delay between simulation and first fraction images was also assessed with an equivalence test.
Results UNASSIGNED
From 107 features evaluated, 58 (54 %) were considered as non-reproducible: 18 were uniformly inconsistent across both phantom and patient images, 9 were specific to phantom-based analysis, and 31 to patient-derived data.
Conclusion UNASSIGNED
Our findings show that a significant proportion of radiomic features extracted from this dual dataset were unreliable. It is essential to discard these non-reproducible elements to refine and enhance radiomic model development, particularly for MR-guided radiotherapy in pancreatic cancer.

Identifiants

pubmed: 39140002
doi: 10.1016/j.phro.2024.100613
pii: S2405-6316(24)00083-6
pmc: PMC11320460
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100613

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Morgan Michalet (M)

Institut du Cancer de Montpellier, Fédération Universitaire d'Oncologie-Radiothérapie d'Occitanie Méditerranée (FOROM), INSERM U1194 IRCM, 208 avenue des apothicaires, 34298 Montpellier, France.
IRCM, Univ Montpellier, ICM, INSERM, 208 avenue des apothicaires, 34298 Montpellier, France.

Gladis Valenzuela (G)

IRCM, Univ Montpellier, ICM, INSERM, 208 avenue des apothicaires, 34298 Montpellier, France.

Pierre Debuire (P)

Institut du Cancer de Montpellier, Fédération Universitaire d'Oncologie-Radiothérapie d'Occitanie Méditerranée (FOROM), INSERM U1194 IRCM, 208 avenue des apothicaires, 34298 Montpellier, France.

Olivier Riou (O)

Institut du Cancer de Montpellier, Fédération Universitaire d'Oncologie-Radiothérapie d'Occitanie Méditerranée (FOROM), INSERM U1194 IRCM, 208 avenue des apothicaires, 34298 Montpellier, France.
IRCM, Univ Montpellier, ICM, INSERM, 208 avenue des apothicaires, 34298 Montpellier, France.

David Azria (D)

Institut du Cancer de Montpellier, Fédération Universitaire d'Oncologie-Radiothérapie d'Occitanie Méditerranée (FOROM), INSERM U1194 IRCM, 208 avenue des apothicaires, 34298 Montpellier, France.
IRCM, Univ Montpellier, ICM, INSERM, 208 avenue des apothicaires, 34298 Montpellier, France.

Stéphanie Nougaret (S)

IRCM, Univ Montpellier, ICM, INSERM, 208 avenue des apothicaires, 34298 Montpellier, France.
Institut du Cancer de Montpellier, Service d'imagerie médicale, 208 avenue des apothicaires, 34298 Montpellier, France.

Marion Tardieu (M)

IRCM, Univ Montpellier, ICM, INSERM, 208 avenue des apothicaires, 34298 Montpellier, France.

Classifications MeSH